Practical Use of Recombinant Human FGF-19

Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized), SKU P1050, provides a defined source of FGF-19 protein for assays that require controlled ligand input. It is a 195-amino-acid, non-glycosylated polypeptide with an approximate molecular weight of 21.8 kDa. The material is produced in Escherichia coli, supplied without an affinity tag, sterile filtered, and lyophilized from concentrated PBS at pH 7.4.

No directly matched paper evidence is used in this article. The recommendations below are based on the product dossier and standard assay-control practices, so they should be treated as an experimental setup guide rather than evidence of a new biological effect.

What This Product Solves

FGF-19 is an endocrine FGF subfamily member whose receptor response is commonly evaluated through FGFR4, with β-Klotho functioning as a co-factor that can enhance ligand-receptor affinity. A defined, tag-free ligand helps reduce uncertainty caused by fusion tags or poorly documented protein preparation when comparing receptor-binding or cell-response conditions.

For an FGF-19 and FGFR4 binding workflow, the product is appropriate for testing interaction with immobilized recombinant human FGFR4. For a Cell proliferation assay with FGF-19, the dossier identifies murine Balb/c 3T3 cells as the activity model. These assays can provide an operational check that the reconstituted material is active under the chosen conditions. In Metabolic regulation research, FGF-19 can be used as a controlled perturbation while investigators measure endpoints related to hepatic triglyceride handling, fatty acid oxidation, glucose metabolism, or insulin sensitivity. Those endpoints remain model-dependent and should not be inferred from the binding or proliferation result alone.

Protocol Parameters

• Assay: Reconstitution and stock preparation; Value: 0.1–1.0 mg/mL; Applicability: Preparation of a concentrated working stock; Rationale: Sterile distilled water or aqueous buffer containing 0.1% BSA is recommended for dissolving the lyophilized powder and limiting nonspecific loss during handling; Evidence basis: Product dossier.
• Assay: FGF-19 and FGFR4 binding ELISA; Value: ED50 less than 150 ng/mL; Applicability: Orientation for a receptor-binding activity check using immobilized recombinant human FGFR4; Rationale: The reported value indicates the product has measurable binding-associated activity in the stated assay format, but it is not a guaranteed concentration-response value for every plate or receptor preparation; Evidence basis: Product dossier.
• Assay: Cell proliferation assay with FGF-19; Value: ED50 less than 150 ng/mL; Applicability: Benchmarking activity in murine Balb/c 3T3 cells; Rationale: This is the stated cellular activity model and should be used as a reference system before transferring the protein to another cell line; Evidence basis: Product dossier.
• Assay: Specific activity assessment; Value: greater than 6.7 × 10³ IU/mg; Applicability: Comparing functional potency between qualified lots or preparations; Rationale: Specific activity provides a mass-normalized activity descriptor and should be interpreted alongside the actual assay response; Evidence basis: Product dossier.
• Assay: Product quality and contamination control; Value: purity greater than 95% and endotoxin below 1 EU/µg; Applicability: Initial suitability review for biochemical and cell-based experiments; Rationale: These specifications support assay planning but do not replace laboratory-specific contamination checks or matrix controls; Evidence basis: Product dossier.
• Assay: Storage workflow; Value: supplied material at or below -20 °C; reconstituted material for 1 month at 2–8 °C or 3 months at -20 to -70 °C; Applicability: Stock management after receipt and reconstitution; Rationale: Aliquoting reduces repeated handling and helps preserve functional consistency; Evidence basis: Product dossier.

Workflow Setup and QC Checklist

1. Reconstitute deliberately

Record the lot, vial condition, and planned stock concentration before opening the vial. Add sterile distilled water or an aqueous buffer containing 0.1% BSA to reach a concentration within the recommended 0.1–1.0 mg/mL range. Mix gently until the powder is dissolved; avoid vigorous foaming and do not assume that a visually clear solution proves retained biological activity. The Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized) product page should be checked alongside the lot-specific documentation before use.

2. Aliquot and assign controls

Prepare single-use or limited-use aliquots and store them according to the stated temperature conditions. Include a vehicle control containing the same reconstitution matrix, a no-ligand control, and a positive assay control where available. For receptor studies, compare receptor-containing wells with appropriate matrix or receptor-free wells. If the contribution of β-Klotho is being examined, use matched conditions with and without the co-factor rather than interpreting one receptor format as universal.

3. Establish an assay benchmark

For the FGF-19 biological activity assay, begin with the dossier-described Balb/c 3T3 proliferation model or the immobilized FGFR4 binding format. Use a concentration series that brackets the reported ED50 rather than selecting one concentration as a universal working dose. Keep incubation time, cell condition, receptor loading, detection reagent, and dilution matrix consistent across the series. Transfer to a different cell line only after confirming that its FGFR4 and β-Klotho status is known or experimentally assessed.

4. Review QC before interpreting biology

Confirm that the reconstituted material is free of visible particles and that the dilution series was prepared without carryover errors. For lot qualification, review the stated SDS-PAGE and HPLC purity values and endotoxin specification. In cell assays, compare protein-treated wells with vehicle and untreated controls and monitor baseline viability independently from the target readout. A response in a proliferation assay should not be described as metabolic regulation unless metabolism-specific endpoints were measured.

The Recombinant Human FGF-19: Assay Reliability Guide complements this protocol with scenario-based controls for proliferation, viability, receptor-binding, and cytotoxicity workflows. For exploratory renal studies, Recombinant Human FGF-19 Renal Workflows extends the same receptor-aware setup while separating testable hypotheses from established product evidence.

Common Failure Modes and Fixes

• Weak or inconsistent activity after reconstitution: Check the buffer composition, confirm complete dissolution, and review whether the protein underwent repeated freeze-thaw handling. Use a fresh aliquot and repeat the benchmark assay before changing the biological interpretation.
• Low FGFR4 signal: Confirm receptor coating, ligand dilution accuracy, and detection performance. If the assay is intended to represent the co-factor-enhanced system, verify β-Klotho availability rather than assuming that FGFR4 alone will produce the expected response.
• High background in binding assays: Inspect blocking, washing, plate uniformity, and nonspecific adsorption. Include receptor-free and matrix-only controls to distinguish ligand binding from plate or reagent background.
• Variable proliferation results: Check cell health, culture consistency, seeding uniformity, serum or medium changes, and assay timing. A proliferation signal can be distorted by baseline growth differences, so normalize only after confirming comparable control wells.
• Apparent activity in the vehicle control: Review the reconstitution buffer, carrier protein, dilution path, and any solvent introduced downstream. Keep the vehicle composition matched across all conditions.

Scope and Limitations

This FGF-19 protein is an E. coli-expressed, tag-free, non-glycosylated preparation. Its stated activity was confirmed in an FGFR4 binding ELISA and a Balb/c 3T3 proliferation assay; those results do not guarantee equivalent potency in primary cells, organoids, animal models, or human tissues. They also do not establish a disease-modifying effect, therapeutic profile, or outcome in renal injury, inflammation, or metabolic disease.

Because no directly matched paper evidence is available for the specific product use described here, researchers should report the lot, reconstitution buffer, stock concentration, dilution matrix, receptor or cell system, controls, and endpoint definition. Interpret negative results cautiously when FGFR4 or β-Klotho expression is uncertain, and interpret positive results within the limits of the measured assay.

Conclusion

Recombinant Human FGF-19 provides a practical, defined ligand for FGFR4 binding, proliferation, and exploratory metabolic signaling workflows. Reliable use depends on controlled reconstitution, aliquot-based storage, receptor-aware controls, and clear separation between product specifications and conclusions generated by the investigator’s model.